Niagen Bioscience (NAGE) Receivables - Net (2011 - 2026)

Niagen Bioscience (NAGE) has 16 years of Receivables - Net data on file, last reported at $13.1 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 84.51% year-over-year to $13.1 million in Q1 2026; TTM through Mar 2026 was $13.1 million, a 84.51% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, up 25.4% from the prior year.
• Receivables - Net for Q1 2026 stood at $13.1 million, up from $9.7 million in the prior quarter.
• Over the last five years, Receivables - Net for NAGE reached as high as $13.1 million in Q1 2026 and fell as low as $2.8 million in Q2 2023.
• Historically, Receivables - Net has averaged $7.0 million across 5 years, with a median of $7.1 million in 2025.
• Across the five-year window, Receivables - Net slumped 66.99% in 2023 and soared 179.21% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $8.5 million in 2022, then slumped by 66.99% to $2.8 million in 2023, then soared by 177.43% to $7.8 million in 2024, then increased by 25.4% to $9.7 million in 2025, then surged by 34.48% to $13.1 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $13.1 million in Q1 2026, $9.7 million in Q4 2025, and $8.5 million in Q3 2025.